US regulators approved CSL Behring’s hemophilia B gene therapy, a one-off infusion that frees patients from regular treatments but costs $3.5 million a dose, making it the most expensive medicine in the world.
CSL Behring’s Hemgenix, administered just once, cut the number of bleeding events expected over the course of a year by 54%, a key study of the therapy found. It also freed 94% of patients from time-consuming and costly infusions of Factor IX, which is currently used to control the potentially deadly condition.
“While the price is a little higher than expected, I do think it has a